Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis Authors: Madeline Sanders, Eunjin Hong, Peter S Chung, Adupa P Rao, Paul Beringer Published: 2024 ABSTRACT AbstractBackgroundOmadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dose, single-arm study was conducted to characterize the pharmacokinetic (PK) profile of omadacycline in people with CF, considering the known alterations in PK observed in this population (NCT04460586, 2020-07-01).MethodsPlasma samples were obtained from nine adults with CF who received a single dose of intravenous omadacycline 100 mg over 0.5 h followed by a 1-week washout and an oral dose of omadacycline 300 mg. The data were analyzed using noncompartmental PK.ResultsThe maximum plasma concentration (Cmax) and area under the curve extrapolated to infinity (AUC0-∞) after intravenous administration of omadacycline were similar between healthy volunteers and people with CF. The absorption kinetics of oral omadacycline, encompassing both the rate (Cmax and time to Cmax [tmax]) and the extent (AUC0-∞), also showed consistency between healthy volunteers and people with CF. The absolute bioavailability of the oral tablet formulation of omadacycline in people with CF (31.2%) was also consistent with that observed in healthy volunteers (34.5%). In comparing the two routes of administration, intravenous omadacycline 100 mg provided plasma exposures equivalent to those with oral omadacycline 300 mg in people with CF, as evidenced by geometric mean ratios for both AUC0-∞ (0.9381; 90% confidence intervals [CI] 0.6783–1.2975) and Cmax (0.7746; 90% CI 0.5478–1.0951).ConclusionsOverall, the similarity in plasma PK observed in this study when comparing healthy volunteers and infected patients indicates that no dosing alterations are necessary when using omadacycline in people with CF.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40262-024-01440-w. Key Points Nontuberculous mycobacteria, particularly the Mycobacterium abscessus complex (MABSC), are pathogens of significant concern in people with cystic fibrosis (CF) because of their association with deterioration of lung function.Omadacycline has potential as a treatment for MABSC infections in CF because of its efficacy against key pathogens, effective penetration into pulmonary secretions, improved tolerability, and good oral bioavailability.This study indicates that, in people with CF, an intravenous dose of omadacycline 100 mg provides plasma exposure equivalent to that of an oral dose of omadacycline 300 mg, with PK parameters comparable to those in healthy volunteers, supporting the use of standard omadacycline dosing. Introduction Cystic fibrosis (CF) is a genetic disorder characterized by a chronic cycle of airway infection, obstruction, and inflammation, leading to progressive loss of lung function and eventual respiratory failure. Nontuberculous mycobacteria (NTM) are increasingly being isolated from the sputum of people with CF (PwCF), with prevalence estimates rising from 1.3% in 1984 to 13.4% in 2014 [1, 2]. The prevalence of NTM increases with age, from 10% in children aged 10 years to over 30% in adults aged > 40 years [1]. Additionally, between 2010 and 2019, the average annual incidence of NTM pulmonary infections among PwCF in the USA was 58.0 cases per 1000 individuals, with a significant annual increase of 3.5% [3]. NTM can cause progressive inflammatory lung damage, a condition termed ‘NTM pulmonary disease’, and PwCF are predisposed to the condition because of the reduced CF transmembrane conductance regulator (CFTR)-mediated reactive oxygen species generation within macrophages leading to reduced intracellular killing [4]. Recent epidemiological studies have demonstrated that the presence of Mycobacterium abscessus complex (MABSC) in the airways of PwCF is associated with a more rapid decline in lung function and higher mortality [1]. Treatment of MABSCpulmonary disease includes an intensive phase with oral azithromycin and several intravenous antibiotics (e.g., amikacin, tigecycline, imipenem, cefoxitin) for 3–12 weeks, followed by a prolonged continuation phase with a daily oral macrolide (preferably azithromycin), inhaled amikacin, and two to three additional oral antibiotics (e.g., moxifloxacin, minocycline, clofazimine, linezolid) [5]. A significant barrier to effective treatment of MABSC pulmonary disease is the limited number of safe and effective antibiotics. Although macrolides have been the mainstay of treatment for many years, their efficacy is limited by reduced susceptibility. Growing evidence has shown that macrolide resistance in M. abscessus can arise through acquired mutations or inducible mechanisms involving the macrolide-inducible erm (41) gene. Recent major studies have reported high overall resistance rates to moxifloxacin (74.1%), ciprofloxacin (82.6%), and imipenem (55.6%) for MABSC [6]. In addition, the risk for acute kidney injury and/or hearing loss is significant in PwCF with prolonged use of amikacin [7]. Tigecycline demonstrates good in vitro activity and is one of the primary antibiotics during the intensive phase of treatment; however, this agent is associated with significant nausea and vomiting and is only available for intravenous administration. A pharmacodynamic study in a hollow fiber model determined that a dose of 100 mg twice daily was needed to achieve the optimal target attainment (>90% stasis), but this dose was estimated to cause nausea/vomiting in nearly 100% of patients [8]. Omadacycline (Fig. 1) offers a potential advancement in the management of infections involving MABSC in CF because of its activity against CF pathogens (e.g., M. abscessus, methicillin-resistant Staphylococcus aureus [MRSA], and Stenotrophomonas maltophilia) [9–12], effective penetration into pulmonary secretions, improved tolerability, and good oral bioavailability [13–18]. The PK of omadacycline have been well described in healthy volunteers, special populations, and patients with complicated skin and skin structure infections [13–16, 18]. The oral absorption is relatively rapid, although its bioavailability is reduced when taken with high-fat meals or dairy products. Omadacycline has a large volume of distribution and low plasma protein binding (21.3%) that is concentration independent [17]. Of particular importance to the present study is the high pulmonary penetration of omadacycline noted in healthy volunteers [16]. Bronchoalveolar lavage studies performed at steady state following intravenous omadacycline 100 mg daily revealed epithelial lining fluid and alveolar macrophage exposures 1.5-fold and 26-fold higher, respectively, than free-drug exposures in plasma. Omadacycline is not metabolized in humans, nor does it act as a substrate, inhibitor, or inducer of major cytochrome P450 enzymes [17]. It is predominantly eliminated through fecal excretion, and no dosage adjustment is necessary for renal or hepatic disease [17]. Regarding known drug–drug interactions, tetracyclines, including omadacycline, are subject to decreased absorption when co-administered with antacids containing aluminum or calcium or with magnesium, bismuth subsalicylate, or iron-containing preparations [14]. Tetracyclines have also been shown to depress plasma prothrombin activity, which may require decreases in anticoagulant doses when used concomitantly [14]. Chemical structure of omadacycline The PKs of many medications have been shown to be altered in PwCF [19, 20]. In general, PwCF demonstrate an increased volume of distribution when expressed in L/kg of body weight and increased total body clearance. In addition, the oral bioavailability of lipophilic medications may be reduced due to pancreatic insufficiency. To our knowledge, no study has evaluated the PK of omadacycline in people with CF. The purpose of this investigation was to characterize the PK of intravenous and oral omadacycline in PwCF and determine whether any dose alteration is needed based on differences in PK. Materials and Methods Participants Nine adults with CF were enrolled in the study. The inclusion criteria required participants to be aged ≥ 18 years and have a diagnosis of CF based on a positive sweat chloride test or a known CF mutation. Exclusion criteria included the presence of an ongoing acute pulmonary exacerbation defined based on clinical signs and symptoms and an acute decline in forced expiratory volume in 1 s (FEV1) of ≥10%, pregnancy or breastfeeding, a serious past allergy to a tetracycline antibiotic, hemoglobin levels below 8 g/dL, or any clinically significant abnormality noted during a physical exam that could interfere with the study. In addition, no alcohol, nicotine, or caffeine-containing products were allowed during the study period. Co-medications were not withheld, allowing participants to continue their routine CF therapies. The study protocol was approved by the University of Southern California institutional review board (HS-20-00513), and all participants provided written informed consent prior to the study. Omadacycline Dosing This study employed a prospective single-dose, single-arm crossover design to characterize the PK of intravenous/oral omadacycline in PwCF. Study participants received a single intravenous dose of omadacycline 100 mg followed by a 1-week washout period and then an oral dose of omadacycline 300 mg. The intravenous formulation of omadacycline was administered over 30 min. Oral tablets were administered with water after a minimum 4-h fasting period. After oral administration, participants were instructed to fast for an additional 2 h and to not consume dairy products, antacids, or multivitamins for 4 h thereafter, in line with recommendations for oral omadacycline administration [17]. Blood Sampling Blood samples were collected immediately before each dosage form (at 0 h [pre-dose]) and at 0.25, 0.5, 1, 2, 3, 4, 8, 12, 24, 48, and 72 h after the end of the infusion or oral dose administration. For the preparation of plasma, whole blood was collected by venipuncture into sodium heparin collection tubes (BD Biosciences). Immediately after collection, the blood samples were centrifuged for 10 min at 1200 rpm at 4 °C. The plasma was then transferred to a secondary polypropylene tube and subjected to another centrifugation for 10 min at 2000 rpm at 4 °C. The resulting supernatant was aliquoted into cryogenic microcentrifuge tubes and stored at −80 °C until further analysis. Analytical Method and Quantification Omadacycline concentrations in human plasma were determined using liquid chromatography-tandem mass spectrometry (Institute of Clinical Pharmacodynamics). The method used was linear (1/x2) over the concentration range of 0.020–5.00 mg/L. The correlation coefficient (r2) values ranged from 0.9987 to 0.9993. For the method quality control samples, the inter-assay coefficient of variance (%CV) ranged from 1.54% to 4.20%, and the inter-assay percent recovery ranged from 99.1% to 105.3%. For the PK analysis, concentration data below the lower limit of quantitation were set to zero if they occurred before the first quantifiable concentration. If they appeared between two reported concentrations or after the last quantifiable concentration, they were treated as missing. Analysis PK analysis was performed using standard noncompartmental methods using WinNonlin Phoenix version 8.4 (Certara Inc.). The maximum plasma concentration (Cmax) and time to maximum concentration (tmax) were determined by visual inspection of the concentration–time profile data. The elimination rate constant (λz) was estimated from the slope of the terminal portion of the concentration–time profile using at least three concentration timepoints. Half-life was calculated as 0.693/λz. The area under the curve (AUC0-∞) was calculated using the linear-up log-down method with an estimation of the terminal area by Clast/λz, where Clast is the last measurable concentration. Total plasma clearance (CL/F) was calculated by dose/AUC0-∞. The volume of distribution at steady state (Vss) was estimated based on the last observed concentration. Absolute bioavailability (F) was determined by the formula: F = (AUC0-∞ [oral] × dose [IV])/(AUC0-∞ [IV] × dose [oral]), where IV indicates intravenous. The mean and standard deviation and the median and interquartile range (IQR) were calculated for the demographic data and PK parameters, both for the overall dataset and when stratified by sex. Sample Size and Statistical Analysis All statistical analyses were performed using SAS software version 9.4 (SAS Institute). We targeted a sample size of 12 participants to describe the PK of omadacycline in PwCF, with an alpha of 0.1 and a power of 0.74–0.98, based on similar studies in healthy volunteers and assuming comparable PK and variability in PwCF [13]. A linear mixed-effects model analysis was performed using PROC MIXED of SAS on log-transformed dose-normalized AUC0-∞ and Cmax values of omadacycline. The analysis of variance model included the route of administration (oral and intravenous) as a fixed effect and the subject as a random effect. The point estimates and the associated 90% confidence intervals (CIs) for the test/reference ratios were calculated by exponentiation of the differences of mean logarithms (test-reference) obtained from the linear mixed-effects model analysis. The least squares means and 90% CIs were exponentiated to the original non-dose-normalized values. Geometric mean ratios (GMRs) and 90% CIs, without dose normalization, were presented for comparison of formulations for AUC0-∞ and Cmax. To evaluate differences in drug exposure between the sexes, geometric mean AUC0–∞ ratios, as well as geometric means for half-life, clearance, and Vss, were calculated. Statistical analyses were performed using Welch’s unpaired t-tests to assess the significance of these differences across all parameters between male and female subjects. Results Study Participants Nine PwCF participated in the study; their baseline characteristics are listed in Table 1. The majority of participants were male. None of the participants routinely used iron supplements, bismuth subsalicylate, or aluminum-containing antacids. One subject (8) used magnesium supplements, and three subjects (6, 8, and 9) used calcium supplements. Eight of nine participants were pancreatic insufficient, with seven receiving pancrelipase supplements; however, they were all well-nourished, as indicated by their median normal body mass index (BMI) of 24.3 (IQR 22.7–25.6). No adverse events related to the study were reported. Table 1Demographics and clinical characteristics of study participantsCharacteristicStudy participants (n = 9)Age (years)37 (31–45 [25–62])Male6 (66.7)Race/ethnicity White5 (55.6) African American1 (11.1) Hispanic3 (33.3)CF-related diabetes6 (66.7)Gastrointestinal reflux disease3 (33.3)Height (cm)172.6 (170.5–177 [157–179.6])Weight (kg)71.2 (67.6–78.2 [63.3–107.5])BMI (kg/m2)24.3 (22.7–25.6 [20.7–37])FEV1 (% predicted)80.0 (59–83 [50–88])All data are presented as n (%) or median (interquartile range [range]) unless otherwise specifiedBMI body mass index; CF cystic fibrosis, FEV1 forced expiratory volume in 1 s Demographics and clinical characteristics of study participants All data are presented as n (%) or median (interquartile range [range]) unless otherwise specified BMI body mass index; CF cystic fibrosis, FEV1 forced expiratory volume in 1 s Plasma PK parameters for intravenous and oral dosing are presented in Table 2 (n = 9). The concentration–time profiles over the first 12 and 72 h for intravenous and oral omadacycline are depicted in Fig. 2 (population) and Fig. 3 (individuals). Of the 214 total plasma samples collected, 196 were post-dose, with only 14 samples below the limit of quantification, representing 7.1% of the post-dose samples. The least squares mean AUC0-∞ for oral omadacycline 300 mg (8.26; 90% CI 6.57–10.38) and intravenous omadacycline 100 mg (8.80; 90% CI 7.00–11.07) were not significantly different (p = 0.74). Similarly, the least squares mean Cmax for oral omadacycline 300 mg (0.54; 90% CI 0.42–0.69) and intravenous omadacycline 100 mg (0.70; 90% CI 0.55–0.89) were not significantly different (p = 0.21). Oral omadacycline 300 mg exhibited drug exposure levels comparable to those observed with the intravenous 100 mg dose, as evidenced by GMRs for both AUC0-∞ (0.94; 90% CI 0.68–1.30) and Cmax (0.77; 90% CI 0.55–1.10). The mean absolute bioavailability was 31.2%, which is consistent with the similar Cmax and AUC0-∞ following an oral dose of 300 mg and an intravenous dose of 100 mg (Fig. 3). Table 2Noncompartmental PK parameter estimates following a single dose of intravenous omadacycline 100 mg or oral omadacycline 300 mg in PwCF parameterIV (100 mg) Oral (300 mg)Mean (%CV)Median (IQR)Mean (%CV)Median (IQR)Cmax (mg/L)0.73 (30.9)0.75 (0.63–0.76)0.60 (40.4)0.65 (0.44–0.70)tmax (h)NANA2.3 (52.5)2.0 (1.0–3.0)AUC0-∞ (mg*h/L)9.23 (32.1)8.59 (6.76–11.96)8.90 (34.8)10.19 (8.35–11.01)FNANA0.312 (44.1)0.340 (0.225–0.427)CL (L/h*kg)0.16 (28.0)0.14 (0.12–0.19)NANAVss (L/kg)3.91 (25.1)3.93 (3.18–4.27)NANAλz (h-1)0.04 (17.3)0.04 (0.03–0.04)0.04 (25.9)0.04 (0.03–0.04)t½-λz (h)19.1 (17.1)18.3 (17.0–21.3)19.0 (22.1)19.0 (16.5–23.0)AUC0-∞ area under the curve extrapolated to infinity, CL clearance, Cmax maximum concentration in plasma, CV coefficient of variation, F bioavailability, IQR interquartile range, NA not applicable, tmax time to Cmax, t½, λz half-life, Vss volume of distribution at steady state, λz terminal elimination rate constant Noncompartmental PK parameter estimates following a single dose of intravenous omadacycline 100 mg or oral omadacycline 300 mg in PwCF AUC0-∞ area under the curve extrapolated to infinity, CL clearance, Cmax maximum concentration in plasma, CV coefficient of variation, F bioavailability, IQR interquartile range, NA not applicable, tmax time to Cmax, t½, λz half-life, Vss volume of distribution at steady state, λz terminal elimination rate constant Mean omadacycline plasma concentrations (± standard deviation) after a single intravenous (IV) dose of omadacycline 100 mg or an oral dose of omadacycline 300 mg over (A) 72 h and (B) the first 12 h Individual omadacycline plasma concentrations (± standard deviation) after a single intravenous (IV) dose of omadacycline 100 mg and a single oral dose of omadacycline 300 mg Following an intravenous dose of omadacycline 100 mg, systemic exposure was comparable between sexes, with a geometric mean AUC0–∞ ratio of 0.78 (90% CI 0.50–1.21; p = 0.363) for males compared with females. Similarly, after an oral dose of omadacycline 300 mg, systemic exposure remained comparable, with a geometric mean AUC0–∞ ratio of 0.83 (90% CI 0.52–1.31; p = 0.461) for males versus females. The geometric means for the half-life were 19.7 h for male subjects and 17.3 h for female subjects (p = 0.180). For clearance, the geometric means were 0.171 L/h*kg for males and 0.124 L/h*kg for females (p = 0.034), whereas the geometric means for Vss were 4.34 L/kg for males and 2.92 L/kg for females (p = 0.003). Discussion CF is characterized by chronic airway obstruction, infection, and inflammation, leading to progressive loss of lung function and eventual respiratory failure. Omadacycline, a tetracycline antibiotic, demonstrates in vitro activity against key CF pathogens such as M. abscessus, MRSA, and S. maltophilia; exhibits lung penetration in healthy subjects; and shows increasing clinical evidence for the treatment of lung infections in PwCF [16, 21–23]. The present study was conducted to evaluate the PK of omadacycline following single-dose intravenous and oral administration in PwCF. Omadacycline, alongside tigecycline and eravacycline, represents a promising class of third-generation tetracycline-based antibiotics effective against rapidly growing mycobacteria. In six previous studies, minimum inhibitory concentrations (MICs) were determined, demonstrating significant in vitro activity of all three drugs against M. abscessus clinical isolates [24]. The MIC50 and MIC90 ranges for omadacycline were 0.12–2 and 0.25–8 μg/mL, respectively. Comparable ranges were observed for tigecycline and eravacycline, with MIC50 and MIC90 values within the ranges of 0.12–1 and 0.25–8 μg/mL, respectively. Generally, omadacycline demonstrated activity similar to or marginally less than tigecycline and eravacycline, with its MICs being equal to or one dilution step higher than those of the latter two agents [24]. However, given the significant post-antibiotic effects associated with tetracycline-class drugs, the ratio of the area under the free concentration–time curve (fAUC) to MIC is a more reliable predictor of in vivo activity [25]. PK investigations into the bronchopulmonary distribution of intravenous omadacycline, tigecycline, and eravacycline have confirmed elevated drug concentrations in unbound plasma, epithelial lining fluid (ELF), and alveolar macrophages [16, 26]. Notably, omadacycline demonstrated high pulmonary penetration, with drug exposures greatly exceeding those of tigecycline and eravacycline. The mean fAUC for omadacycline was approximately 5.5-fold higher in ELF and 8-fold higher in alveolar macrophages than for tigecycline and about 3.5-fold higher in ELF and 7.5-fold higher in alveolar macrophages than for eravacycline [16, 26]. Omadacycline’s effective tissue penetration, including into pulmonary secretions, may be related to its predicted moderate lipophilicity, which aids diffusion through lipid-rich membranes, and low protein binding, which maintains a higher concentration of free drug available for tissue distribution [16, 17, 27]. To our knowledge, this is the first study to evaluate the PK of omadacycline in PwCF. The principal finding of the PK analysis was that the absolute bioavailability and tmax of the oral tablet formulation of omadacycline are similar in PwCF (31.2%, mean 2.3 h) and healthy volunteers (34.5%, median 3 h) [13]. Additionally, the Cmax and AUC0-∞ values after a single intravenous or oral dose of omadacycline in PwCF are also comparable to those reported in healthy volunteers [13, 14]. Furthermore, the clearance and Vss values (11.9 L/h and 291 L, respectively) in PwCF fall well within the range of published values in healthy volunteers following an intravenous administration of omadacycline 100 mg (8.8–17.1 L/h and 190–353 L, respectively) [18]. These data indicate that no dose adjustments are needed for PwCF. In comparing the two routes of administration, intravenous omadacycline 100 mg provided equivalent plasma exposures to oral omadacycline 300 mg in PwCF. After stratifying the PK parameters by sex, we observed initial differences in drug exposure (AUC0–∞), half-life, clearance, and Vss between male and female subjects (Tables S1 and S2 in the supplementary material). The influence of sex on omadacycline PK is well established in the literature [17, 18]. Our results aligned with previous studies, indicating that female subjects had slightly higher mean drug exposure after both intravenous and oral administration, along with longer half-lives [17, 18]; however, these differences were not statistically significant. In contrast, clearance and Vss showed statistically significant differences. Despite these findings, the small sample size in our cohort and the absence of differences in plasma exposures (AUC0–∞) suggest that the clinical relevance is minimal. The FDA label indicates that no clinically significant differences in omadacycline PK based on sex have been observed, and no dose adjustments are necessary [14], which may also be relevant for the population in this study. CF-associated alterations in PK have been studied and documented in the literature for some time, and it has been generally concluded that, compared with healthy adults, the CF population exhibits slower absorption rates, equal or lower bioavailability, higher clearance, and equal or increased distribution volumes [28]. A recent meta-analysis estimated the overall impact of CF on intravenous drug disposition and identified influencing factors related to both drug disposition and pathophysiology. It similarly found increased volumes of distribution and clearance, with these differences being largely attributed to body composition variations, such as reduced fat and muscle mass due to malnutrition [29]. Before the introduction of highly effective CFTR modulator therapies, research consistently indicated that PwCF typically had lower levels of fat-free mass, lean body mass, skeletal muscle, and albumin than the general population [30]. However, over the past two and a half decades, these treatment advances have led to significant improvements in nutritional status and albumin levels, largely eliminating the differences in body composition between PwCF and healthy people [31–33]. Given this enhanced growth and BMI, recent investigations into the PK of drugs in PwCF versus healthy controls have not demonstrated significant differences. The similarity in both the average BMI and the PK of omadacycline between PwCF and healthy volunteers supports this hypothesis [13, 14, 18]. Additionally, given omadacycline's low protein binding [17] and the normalization of albumin levels in PwCF [32], significant variations in free drug concentrations within this population are unlikely. The study faced several limitations. PwCF are highly vulnerable to bacterial and viral respiratory infections, making recruitment for the clinical trial challenging during the COVID-19 pandemic and resulting in a relatively small sample size of nine participants. Notably, the point value GMR for AUC0-∞ (0.94) falls within the FDA bioequivalence acceptance criteria of 0.8–1.25. However, the CI (0.68–1.30) is slightly wider, which is unlikely to have clinical significance and is likely due to the small sample size. Additionally, intersubject variability in PK parameters was greater after oral than intravenous omadacycline administration and greater than that reported in healthy volunteers. This may be related to differences in pancreatic insufficiency in PwCF. Specifically, subjects 3 and 6 exhibited notably low drug exposure after oral omadacycline administration. For subject 3, this can be attributed to a combination of rapid drug clearance and suboptimal gut absorption, as their clearance following intravenous administration was substantially higher, and both bioavailability and Cmax after oral administration were below the trial average (16.9 L/h, 22.5%, and 0.380 mg/L, respectively). For subject 6, the low drug exposure was almost exclusively due to poor gut absorption, as indicated by the exceptionally low bioavailability and Cmax after oral administration (10.7% and 0.186 mg/L, respectively). It is plausible that CF-related pancreatic insufficiency was particularly severe in these two subjects, given their elevated daily doses of pancreatic enzymes compared with the trial population average. Additionally, subject 6, who was not on CFTR modulator therapy and had the lowest BMI, exhibited significant absorption difficulties, underscoring the challenges that some PwCF may face despite enzyme supplementation. Lastly, our study did not include a control population to directly compare the PK in PwCF. Conclusions Overall, the similarity in PK observed in PwCF in this study when compared with healthy volunteers and infected patients indicates that the standard dosing of omadacycline 300 mg once daily is appropriate for PwCF [13, 22]. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 29 KB) Declarations Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium. This study was supported by Paratek Pharmaceuticals, Inc. as an investigator-initiated grant. Conflicts of Interest The authors have no conflicts of interest to declare. Ethics Approval The study protocol was approved by the University of Southern California institutional review board (HS-20-00513), and the study was conducted in compliance with the ethical standards established in the 1964 Declaration of Helsinki and its subsequent amendments. Consent for publication Written informed consent for publication of identifiable details, including clinical data, was obtained from the patient (or their legal guardian) prior to submission of this manuscript, in accordance with Adis Publishing ethical guidelines. Consent to Participate All participants provided written informed consent before the study. Availability of Data and Material The data that support the findings of this study are available from the corresponding author upon reasonable request. Data sharing will be subjected to standard data use agreements from the University of Southern California. Author Contributions All authors contributed to the study conception and design. Data were collected by Peter Chung and Adupa Rao. Data were analyzed by Eunjin Hong, Madeline Sanders, and Paul Beringer. The first draft of the manuscript was written by Madeline Sanders, and all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript. Footnotes Madeline Sanders and Eunjin Hong contributed equally to this work. References Associated Data Supplementary Materials Supplementary file1 (DOCX 29 KB)